Materials and Methods: Between March and June 2009, an internet-based
survey was performed among board-certified urologists of the EAU who treated >= 10 patients with metastatic PCa annually. Results: Questionnaires completed by 200 LDC000067 solubility dmso urologists from 12 European countries including 27,442 PCa patients were used for analyses. On average, 22% of the patients presented in stage IV, 15% had bone metastases and 10% received BPs. In most countries, BPs were used to the same extent in hormone-naive and castration-resistant PCa (CRPC). A total of 23% of urologists prescribed chemotherapy in patients with hormone-sensitive PCa, and 55% of the urologists did not administer androgen deprivation NCT-501 purchase maintenance therapy in patients with CRPC. Conclusions: BPs were frequently used in PCa with bone metastases, although current guidelines recommend their use only in CRPC. Standardized multidisciplinary
educational programs should be developed in order to prevent non-indicated early chemotherapy in hormone-sensitive patients and to stimulate maintenance of androgen deprivation therapy in CRPC patients. Also, programs facilitating home infusions for patients who need intravenous BPs are needed in specific countries to optimize treatment of CRPC. Copyright (C) 2012 S. Karger AG, Basel”
“Pregnancy associated with ovarian tumors was reviewed over a 20-year period to determine the maternal and fetal outcome in patients undergoing surgery during pregnancy.
A retrospective study of 94 cases of ovarian tumors treated surgically during pregnancy was investigated for incidence, clinico-pathological FaraA features and outcome in a teaching hospital between June 1987 and May 2007.
The overall incidence of ovarian tumor in pregnant women
was 1 in 505 (0.2%) deliveries. Diagnosis of 69.2% tumors resulted in the first and second trimesters of pregnancy. Twenty-two (23.4%) patients presented as an emergency at different periods of gestation and 16 (17.1%) tumors were incidentally discovered at cesarean section which underlines the significance of examining the ovaries routinely at cesarean section. Benign teratoma (39.4%) and serous cystadenoma (24.5%) were the most common types of ovarian tumors found in the study. The incidence of malignant tumors was 5.3%. Tumors with low malignant potential comprised 40% of malignancy. The miscarriage rate after surgery was 44.4% in the first trimester compared with 16.6% in the second trimester. The preterm birth rate was 4.3% in the series.
The value of clinical and ultrasound examinations in early pregnancy as a diagnostic aid is highlighted. Whenever an ovarian tumor is detected in pregnancy, malignancy should always be suspected. Treatment of an ovarian tumor in pregnancy should be tailored according to the age, parity, clinical presentation, gestational age and histopathology of the tumor.